Our Advances in 2009 and Coming in 2010
In 2009, we added several breakthrough products—such as the Pipeline™ Embolization Device and TurboHawk™ Plaque Excision System—to our extensive endovascular portfolio to improve patient outcomes and expand our procedural penetration. We believe that these new products, as well as the clinical studies that are underway, will drive continued growth and deliver enhanced value to our shareholders.
Moving forward, we will continue to develop and introduce breakthrough products, demonstrate the efficacy of these products in clinical trials, and leverage our extensive global presence.
We invite you to learn more about our key neurovascular and peripheral vascular product offerings.
Print
